Healthcare provider profile · identity verified

Liza Meyerhardt, MD

Internal Medicine · NEEDHAM, MA · NPI 1962507426

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	456	147
Lisinopril	Lisinopril	415	119
Levothyroxine Sodium	Levothyroxine Sodium	295	81
Rosuvastatin Calcium	Rosuvastatin Calcium	249	71
Amlodipine Besylate	Amlodipine Besylate	231	64
Losartan Potassium	Losartan Potassium	184	48
Trazodone Hcl	Trazodone Hcl	174	45
Omeprazole	Omeprazole	152	45
Simvastatin	Simvastatin	148	40
Alendronate Sodium	Alendronate Sodium	128	31
Hydrochlorothiazide	Hydrochlorothiazide	114	41
Sertraline Hcl	Sertraline Hcl	97	35
Metformin Hcl Er	Metformin Hcl	95	22
Metoprolol Succinate	Metoprolol Succinate	93	26
Atenolol	Atenolol	92	28
Citalopram Hbr	Citalopram Hydrobromide	87	26
Gabapentin	Gabapentin	79	26
Lorazepam	Lorazepam	78	40
Bupropion Xl	Bupropion Hcl	76	19
Famotidine	Famotidine	58	13
Alprazolam	Alprazolam	55	18
Irbesartan	Irbesartan	49	16
Furosemide	Furosemide	45	14
Eliquis	Apixaban	44	11
Sumatriptan Succinate	Sumatriptan Succinate	44	suppressed
Allopurinol	Allopurinol	43	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	40	11
Albuterol Sulfate Hfa	Albuterol Sulfate	39	16
Tamsulosin Hcl	Tamsulosin Hcl	39	suppressed
Xarelto	Rivaroxaban	37	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	36	suppressed
Finasteride	Finasteride	34	suppressed
Clonazepam	Clonazepam	31	suppressed
Mirtazapine	Mirtazapine	31	suppressed
Prednisone	Prednisone	31	suppressed
Tramadol Hcl	Tramadol Hcl	31	suppressed
Ezetimibe	Ezetimibe	30	suppressed
Valsartan	Valsartan	30	suppressed
Estradiol	Estradiol	29	11
Potassium Chloride	Potassium Chloride	29	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	29	suppressed
Duloxetine Hcl	Duloxetine Hcl	27	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	25	suppressed
Fluticasone Propionate	Fluticasone Propionate	25	suppressed
Valacyclovir	Valacyclovir Hcl	24	suppressed
Chlorthalidone	Chlorthalidone	23	suppressed
Synthroid	Levothyroxine Sodium	22	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	22	12
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	21	18
Oxycodone Hcl	Oxycodone Hcl	21	11
Spironolactone	Spironolactone	21	suppressed
Celecoxib	Celecoxib	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	17	suppressed
Metformin Hcl	Metformin Hcl	17	suppressed
Torsemide	Torsemide	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Azithromycin	Azithromycin	15	14
Linzess	Linaclotide	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Tradjenta	Linagliptin	14	suppressed
Acyclovir	Acyclovir	13	suppressed
Amiloride Hcl	Amiloride Hcl	13	suppressed
Azelastine Hcl	Azelastine Hcl	13	suppressed
Carvedilol	Carvedilol	13	suppressed
Clopidogrel	Clopidogrel Bisulfate	13	suppressed
Jardiance	Empagliflozin	13	suppressed
Methenamine Hippurate	Methenamine Hippurate	13	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	13	suppressed
Fluvastatin Er	Fluvastatin Sodium	12	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Nystatin	Nystatin	12	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	12	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Myrbetriq	Mirabegron	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error